A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease

Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Study ID
NCT06935929
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Ustekinumab - Standard Dosage — BIOLOGICAL
    Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous dose of 90 mg UST at week 8.Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.

Study Details

From January 2020 to January 2025, Crohn's disease (CD) patients and gender- and age-matched normal controls were collected from the Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. The aim of this research is to explore the associations of microribonucleic acids (miRNAs) gene polymorphisms with the risk and clinicopathological characteristics of CD, and to analyze the effects of miRNAs gene variantions on the clinical response of ustekinumab (UST) treatment in CD patients at week 8.

Key Dates

Start date
Jan 1, 2020
Status verified
Apr 2025
Primary completion
Jan 1, 2025
Completion
Jan 1, 2025

Study Design

Enrollment
839 participants (actual)

Arms

  • Arm: CD patients
    Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous (SC) dose of 90 mg UST at 8 weeks. Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.
  • Arm: normal controls
    no biological agents treatment

Primary Outcome Measure

the genotypes of miRNAs [ Time Frame: Baseline ]

Related Studies